ScienceGSK licenses Chinese firm’s cancer drug in deal worth up to $750 million
British pharmaceutical giant GSK has agreed to acquire full global rights to a cancer drug from Chengdu-based Chimagen Biosciences for up to $750 million. The T-cell engager is being developed for multiple myeloma, highlighting China’s growing role in global biotechnology.
S
South China Morning Post★★☆☆☆2026-09-16 02:00Original
GSK licenses Chinese firm’s cancer drug in deal worth up to $750 million
Science